Abstract: Primary liver cancer is a very common malignant tumor with especially higher incidence in China， very tough treatment and poor prognosis， which mainly consisted of hepatocellular carcinoma （HCC）. The pathogenesis， clinical features， biological behavior， prognosis and treatment selection in Chinese patients are markedly different from those patients in western countries. It is of great significance to explore reasonable treatment strategies of Chinese population. Sorafenib is an oral， multi-targeted， multi-kinase inhibitor， which has been proved to prolong the survival of patients with advanced HCC by large scale， international clinical studies. Sorafenib has been used in China for more than 6 years and demonstrated its good efficacy and safety. However， there are many shortcomings of it. Recently， the domestic scholars have carried out many clinical studies of sorafenib monotherapy and in combination with other drugs or methods to improve its efficacy. This paper comprehensively reviews current situation and progress of related studies.